NORD is very grateful to Jeffrey Sugarman MD, PhD, Pediatric and Adult Dermatology, Medical Director Redwood Family Dermatology, Associate Clinical Professor in Dermatology and Family Medicine, University of California, San Francisco and Prof. Dr. Christian Hafner, Department of Dermatology, University of Regensburg, Regensburg, Germany, for assistance in the preparation of this report.
Synonyms of Schimmelpenning Syndrome
- Jadassohn nevus phacomatosis
- Jadassohn sebaceous nevus syndrome
- linear sebaceous nevus sequence
- Schimmelpenning-Feuerstein-Mims syndrome
- No subdivisions found.
Schimmelpenning syndrome is a rare multisystem disorder characterized by sebaceous nevus associated with other abnormalities outside the skin which most commonly affect the brain, eyes and bones. The skin lesions associated with this disorder are called sebaceous nevus because they consist of an increased number of sebaceous glands (small oil-producing glands in the skin) along with an overgrowth (hyperplasia) of the epidermis and dilated apocrine glands. Sebaceous nevus is the most common type of organoid epidermal nevi (which broadly encompass abnormally formed adnexal skin elements such as hair follicles and glands within the skin). Epidermal nevi are usually present at birth (congenital), although they might not be identified until later during childhood or after puberty. Affected individuals may also have abnormalities affecting the brain such as seizures or intellectual impairment, the eyes such as clouding (opacity) of the cornea or partial absence of tissue of the iris or retina (coloboma), and the skeleton such as spinal malformations, craniofacial defects, and deformities of the arms and legs. Schimmelpenning syndrome occurs randomly for no apparent reason (sporadically) during the formation and development of the embryo (embryogenesis), most likely due to a mutation of a gene that occurs after fertilization (postzygotic mutation) and is present in only some of the cells of the body (mosaic pattern).
In the past, the term "epidermal nevus syndrome" was used to describe Schimmelpenning syndrome. Some authors still use these terms interchangeably. However, epidermal nevus syndrome no longer refers to a single entity, but rather represents a group of distinct, but related multisystem disorders. Additional terms used to describe Schimmelpenning syndrome include nevus sebaceus syndrome, Schimmelpenning-Feuerstein-Mims syndrome, linear sebaceous nevus sequence, nevus sebaceous of Jadassohn, sebaceous nevus syndrome, Jadassohn nevus phacomatosis and Jadassohn sebaceous nevus syndrome.
The specific symptoms and severity of Schimmelpenning syndrome can vary greatly from one person to another. It is important to note that affected individuals may not have all of the symptoms discussed below. Affected individuals should talk to their physician and medical team about their specific case, associated symptoms and overall prognosis.
The characteristic skin lesion that affects individuals with Schimmelpenning syndrome is a sebaceous nevus, which is a type of epidermal nevus. The scalp, neck and mid-facial area are most often affected. The arms, legs and trunk may also be affected. Sebaceous nevi are usually salmon or yellowed colored, hairless, smooth patches. Eventually (usually around puberty) they become more pronounced and may appear scaly, warty or thickened. When the scalp is involved, large lesions may be present and patchy areas of hair loss (alopecia) may occur. Sebaceous nevi can be prominent and easily noticeable at birth or be subtle and easily missed. Sometimes, sebaceous nevi do not become apparent until after puberty when they go through the above mentioned changes. The lesions, apart from their appearance, usually do not cause additional symptoms.
Sebaceous nevi often occur as isolated findings and usually are not associated with any abnormalities in other organs. However, when they occur with additional extra-cutaneous symptoms, the terms, Schimmelpenning syndrome or nevus sebaceus syndrome, are appropriate. Some researchers have noted that epidermal nevi on the head and face appear more likely to be associated with malformations of the brain, eyes and cranial bones.
Neurological abnormalities often occur in individuals with Schimmelpenning syndrome including seizures, delays in attaining developmental milestones (developmental delays), intellectual impairment, damage to certain cranial nerves and abnormalities affecting certain structures of the brain. Such abnormalities include one side of the brain being larger than the other (hemimegalencephaly), malformation (dysplasia) of the certain brain vessels, absence (agenesis) of the bundle of nerves that connects the two cerebral hemispheres (corpus callosum), and defects of the folds of the brain including a smooth brain that lacks the distinctive folds (agyria), abnormally small folds (microgyria) and abnormally thickened folds (pachygyria).
Individuals with Schimmelpenning syndrome may also have Dandy-Walker malformation, a rare malformation of the brain that is present at birth (congenital). It is characterized by an abnormally enlarged space at the back of the brain (cystic 4th ventricle) that interferes with the normal flow of cerebrospinal fluid through the openings between the ventricle and other parts of the brain (foramina of Magendia and Luschka). Excessive amounts of fluid accumulate around the brain and cause abnormally high pressure within the skull, swelling of the head (congenital hydrocephalus), and neurological impairment. Motor delays and learning problems may also occur. Dandy-Walker malformation is a form of "obstructive" or "internal noncommunicating hydrocephalus", meaning that the normal flow of cerebrospinal fluid is blocked resulting in the widening of the ventricles. Dandy-Walker malformation is often associated with partial agenesis of part of the cerebellum known as the cerebellar vermis. (For more information on this disorder, choose "Dandy-Walker" as your search term in the Rare Disease Database.)
Ocular abnormalities also occur in Schimmelpenning syndrome including a partial absence of tissue (coloboma) from the colored portion of the eye (iris) or the membrane lining the back of the eyes (retina), clouding (opacity) of the cornea, crossed eyes (strabismus), defects of the optic nerve and scarring degeneration or detachment of the retina. Some individuals may have a benign, yellowish-white, fatty tumor on the outer portion of the eyeball (epibulbar lipodermoid). A sebaceous nevus on the face can potentially involve structures in the eye including the eyelids and the thin, clear membrane that covers the outer surface of the eye (conjunctiva).
Affected individuals may also have skeletal malformations including abnormal curvature of the spine, dislocation of the hip, and deformities of the limbs. Craniofacial defects such as an unusually prominent forehead (frontal bossing), underdeveloped nasal and orbital bones and asymmetry of the skull may also occur. Additional skeletal malformations may include bone cysts, underdevelopment of the pelvis and incomplete formation of certain bony structures including the ankle, foot and bones of the spinal column (vertebrae).
Individuals with Schimmelpenning syndrome may also develop vitamin D-resistant rickets, a condition characterized by bow deformities of the legs, pain in the legs and progressive softening of the bone structure. In children, growth rates may be slow, ultimately resulting in short stature. Affected individuals may be prone to fractures.
According to the medical literature, sebaceus nevi are associated with an increased risk (approximately 25 % of affected individuals) of developing secondary benign skin tumors such as trichoblastoma or syringocystadenoma papilliferum, whereas malignant secondary tumors (basal cell carcinoma, squamous cell carcinoma, sebaceous carcinoma) on the basis of a sebaceous nevus are very rare but cannot be excluded.
The exact cause of Schimmelpenning syndrome is unknown. The disorder is believed to be caused by a mutation in a gene that occurs after fertilization of the embryo (postzygotic mutation), most likely early during embryonic development. Affected individuals have some cells with a normal copy of this gene and some cells with the abnormal gene (mosaic pattern). This may be referred to as having two distinct cell lines in the body. The variability of symptoms associated with Schimmelpenning syndrome is due in part to the ratio of healthy cells to abnormal cells. When all cells have the abnormal gene, the condition is not compatible with life. Researchers believe that these postzygotic mutations occur randomly for no apparent reason (sporadically).
Recent research has identified two individuals with Schimmelpenning syndrome who had postzygotic mutations of the KRAS and HRAS genes, respectively. In addition, more than 90% of individuals with a sebaceous nevus (in the absence of associated symptoms) revealed HRAS and KRAS mutations. Further research is necessary to confirm that the involvement of these genes play a role in the development of certain cases of Schimmelpenning syndrome. More research is also necessary to identify the exact underlying molecular mechanisms that are involved in the development of Schimmelpenning syndrome.
Schimmelpenning syndrome affects males and females in equal numbers. The exact prevalence and incidence of the disorder in the general population are unknown. Epidermal nevi (as an isolated finding or a part of a syndrome) have been reported to occur in approximately 1 to 3 per 1,000 live births.
Phakomatosis pigmentokeratotica is a form of epidermal nevus syndrome characterized by the presence of a sebaceous nevus and a condition known as speckled lentiginous nevus of the papular type. Speckled lentiginous nevus is characterized by large, light-brown discoloration of the skin, superimposed by multiple darkened (melanocytic) spots (papules). While sebaceous nevus is present at birth, the characteristic papules of speckled lentiginous nevus may not develop until later in life, whereas the café-au-lait background macules showing a checkerboard arrangement tend likewise to be present in the newborn. Individuals with phacomatosis pigmentokeratotica may also develop additional abnormalities, especially neurological and skeletal abnormalities. Neurological abnormalities include seizures, intellectual impairment, muscle weakness, paralysis on one side of the body (hemiparesis), underdevelopment of one side of the boy (hemiatrophy), excessive sweating (hyperhidrosis), and cutaneous dysesthesia, a condition in which touching the skin causing a feeling of unpleasantness. Skeletal abnormalities may include abnormal side-to-side curvature of the spine (scoliosis) and vitamin D-resistant rickets, a condition characterized by bowing deformities of the legs, pain in the legs and progressive softening of the bone structure. In children, growth rates may be slow, ultimately resulting in short stature. Affected individuals may be prone to fractures. Additional findings that have been reported in this disorder include hearing loss in one ear, crossed eyes (strabismus), droopy of the upper eyelid (ptosis) and narrowing of the aorta (aortic stenosis). (For more information, choose "epidermal nevus syndromes" as your search term in the Rare Disease Database.)
A diagnosis of Schimmelpenning syndrome is made based upon identification of characteristic symptoms (e.g., a sebaceous nevus along with abnormalities affecting other organ systems), a detailed patient history and a thorough clinical evaluation.
Clinical Testing and Work-Up
In some cases, a small sample of affected skin may be taken for microscopic study (biopsy). Additional tests may be required to detect the presence and extent of associated symptoms. Such tests include a skeletal survey, a complete ophthalmologic exam, chests x-rays and specialized imaging techniques to evaluate the brain. Such imaging techniques may include computerized tomography (CT) scanning and magnetic resonance imaging (MRI). Whether a child with a sebaceous nevus should undergo such imaging techniques is controversial. Some researchers believe that these tests should be avoided unless there are clinical signs of central nervous system involvement.
The treatment of Schimmelpenning syndrome is directed toward the specific symptoms that are apparent in each individual. Treatment may require the coordinated efforts of a team of specialists. Pediatricians, pediatric neurologists, dermatologists, orthopedists, orthopedic surgeons, ophthalmologists, and other healthcare professionals may need to systematically and comprehensively plan an affect child's treatment.
The specific therapeutic procedures and interventions for individuals with Schimmelpenning syndrome will vary, depending upon numerous factors including the specific symptoms present, the extent of the disorder, an individual's age and overall health, tolerance of certain medications or procedures, personal preference and other factors. Decisions concerning the use of particular therapeutic interventions should be made by physicians and other members of the healthcare team in careful consultation with the patient and/or parents based upon the specifics of his or her case; a thorough discussion of the potential benefits and risks, including possible side effects and long-term effects; patient preference; and other appropriate factors.
Surgery may be performed to improve cosmetic appearance of individuals with Schimmelpenning syndrome. In the past, surgery was recommended because of the risk of malignancy. However, now that the risk of malignancy is less than previously believed, this view is no longer advocated, especially if surgery will be disfiguring. In addition, the surgical excision of a lesion may not always be possible due to the specific location of the nevus.
Additional therapies for Schimmelpenning syndrome depend upon the specific abnormalities present and usually follow standard guidelines. For example, epilepsy may be treated by anti-seizure medications and certain skeletal and ocular malformations may also be treated surgically. In the medical literature, several cases have been reported where neurosurgery has been used to treat individuals with Schimmelpenning syndrome and epilepsy.
Additional therapies that may be used to treat individuals with Schimmelpenning syndrome include remedial education, physical therapy and occupational therapy all of which should be individualized. Genetic counseling may be of benefit for affected individuals and their families.
Because the yet identified KRAS and HRAS mutations in Schimmelpenning syndrome cause an activation of the RAS-RAF-MAPK signaling pathway and inhibitors of this pathway are already available, a possible treatment of severely affected young patients with the inhibitors has to be considered in the future (e.g., in clinical trials) to possibly improve the associated abnormalities of organs such as the brain.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Toll-free: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, in the main, contact:
Organizations related to Schimmelpenning Syndrome
Jones KL. Ed. Smith’s Recognizable Patterns of Human Malformation. 6th ed. Elsevier Saunders, Philadelphia, PA; 2006:576.
Sugarman JL, Frieden IL. Epidermal Nevus Syndromes. In: Neurocutaneous Syndromes, Roach ES, Miller VS, eds. 2004 Cambridge University Press, Cambridge, UK. Pp. 88-103.
Prayson RA. Epidermal Nevus Syndrome. NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:105-106.
Gorlin RJ, Cohen MMJr, Hennekam RCM. Eds. Syndromes of the Head and Neck. 4th ed. Oxford University Press, New York, NY; 2001:484-485.
Groesser L, Herschberger E, Ruetten A, et al. Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet. 2012;44:783-787. http://www.ncbi.nlm.nih.gov/pubmed/22683711
Moody MN, Landau JM, Goldberg LH. Nevus sebaceous revisited. Pediatr Dermatol. 2012;29:15-23. http://www.ncbi.nlm.nih.gov/pubmed/21995782
Happle R. The group of epidermal nevus syndromes. Part I. Well defined phenotypes. J Am Acad Derm. 2010;63:1-22. http://www.ncbi.nlm.nih.gov/pubmed/20542174
Happle R. The group of epidermal nevus syndromes. Part II. Less well defined phenotypes. J Am Acad Derm. 2010;63:25-30. http://www.ncbi.nlm.nih.gov/pubmed/20542175
Brandling-Bennett HA, Morel KD. Epidermal nevi. Pediatr Clin North Am. 2010;57:1177-1198. http://www.ncbi.nlm.nih.gov/pubmed/20888465
Amato C, Elia M, Schepis C. Schimmelpenning syndrome: a kind of craniofacial epidermal nevus associated with cerebral and ocular MR imaging abnormalities. AJNR Am J Neuroradiol. 2010;31:E47-48. http://www.ncbi.nlm.nih.gov/pubmed/20299435
Greene AK, Rogers GF, Mulliken JB. Schimmelpenning syndrome: an association with vascular anomalies. Cleft Palate Craniofac J. 2007;44:208-215. http://www.ncbi.nlm.nih.gov/pubmed/17328648
Sugarman JL. Epidermal nevus syndromes. Semin Cutan Med Surg. 2004;23:145-157. http://www.ncbi.nlm.nih.gov/pubmed/15295924
Happle R. Gustav Schimmelpenning and the syndrome bearing his name. Dermatology. 2004;209:84-87. http://www.ncbi.nlm.nih.gov/pubmed/15316159
The information in NORD’s Rare Disease Database is for educational purposes only. It should never be used for diagnostic or treatment purposes. If you have questions regarding a medical condition, always seek the advice of your physician or other qualified health professional. NORD’s reports provide a brief overview of rare diseases. For more specific information, we encourage you to contact your personal physician or the agencies listed as “Resources” on this report.
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
Report last updated: 2012/11/06 00:00:00 GMT+0
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.